Abstract
Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].
MeSH terms
-
Animals
-
Clinical Trials as Topic / methods
-
Clinical Trials as Topic / statistics & numerical data
-
Drug Industry / legislation & jurisprudence
-
Drug Industry / methods*
-
Humans
-
Indoles / chemistry
-
Indoles / pharmacology*
-
Indoles / therapeutic use*
-
Pyrrolidines / chemistry
-
Pyrrolidines / pharmacology*
-
Pyrrolidines / therapeutic use*
-
Serotonin Receptor Agonists / pharmacology
-
Serotonin Receptor Agonists / therapeutic use
-
Tryptamines
Substances
-
Indoles
-
Pyrrolidines
-
Serotonin Receptor Agonists
-
Tryptamines
-
eletriptan